Correlation Between Psychiatric Morbidity And Single Photon Emission Computed Tomography Findings In Juvenile Rheumatoid Arthritis.

Thesis

Submitted for fulfillment of Ph D. In Childhood Studies Medical Studies Department (Child Health and Nutrition)

By

Fatma Sayed Sayed Mahrous M.B.B.Ch., M.Sc in Pediatrics Under Supervision of

Prof. Dr. Zeinab Bishry Abd EL Hamid

Professor of Psychiatry Faculty of Medicine Ain Shams University

Prof. Dr. Elham Mohammad Hossny

Professor of Pediatrics Faculty of Medicine Ain Shams University

Prof. Dr. Hala Mahmoud Abou Senna

Professor of Radiodiagnosis Faculty of Medicine Ain Shams University

Dr. Mona Medhat Reda

Assistant Professor of Psychiatry Medical Studies Department Institute of Postgraduate Childhood Studies

Dr.Amr Lotfy Farag

Assistant Professor of Radiation Oncology Faculty of Medicine Ain Shams University

Institute of Postgraduate Childhood Studies
Ain Shams University
2010

العلاقة بين الا ضطراب النفسى و التغيرات في الاشعة المقطعية احادية الفوتون على المخ في مرض التهاب المفاصل المعروف بروماتويد الصغار.

رسالة مقدمة من الطبيبة/ فاطمة سيد سيد محروس بكالوريوس طب و جراحة- ماجستير طب الاطفال توطئة للحصول على درجة دكتوراة الفلسفة في در اسات الطفولة. قسم الدراسات الطبية.

(صحة و تغذية الطفل)

تحت اشراف

استاذ دكتور زينب بشرىعبد الحميد

استاذ الطب النفسي

كلية الطب- جامعة عين شمس

استاذ دكتور الهام محمد حسنى

استاذ طب الاطفال

كلية الطب- جامعة عين شمس

استاذ دكتور \هالة محمود ابو سنة

استاذ الاشعة التشخيصية

كلية الطب- جامعة عين شمس

دکتور\ منی مدحت رضا

استاذ مساعد الطب النفسيبقسم الدراسات الطبية

معهد الدراسات العليا للطفولة

دكتور\عمرو لطفى فرج

استاذ مساعد علاج الاورام.

كلية الطب- جامعة عين شمس

معهد الدراسات العليا للطفولة جامعة عين شمس ٢٠١٠

Acknowledgments

First and foremost, I thank "Allah", giver of all knowledge and wisdom, the Gracious, the Merciful.

I wish to express my sincere gratitude to prof. Dr. Zeinab Bishry Abd El-Hamid, prof. of Psychiatry, Ain Shams University for the continuous supervision, teaching and for her valuable help and assistance.

I consider it an enormous privilege to work under the supervision of Prof. Dr. Elham Mohammad Hossny, Prof of Pediatrics, Ain Shams University. Who guided me a lot in completing this work.

I would like to express my deep thanks and sincere gratitude to Prof. Dr. Hala Mahmoud Abou Senna, Professor of Radiodiagnosis, Ain Shams University. I am greatly indebted to her for her great help, continued support and guidance in completing this work.

My deep thanks and sincere gratitude are due to Dr. Mona Medhat Reda, Assistant Prof. of Psychiatry, Institute of Postgraduate Childhood Studies, who helped a great deal. Her valuable guidance, supervision and her continuous support are behind accomplishing this work.

I am grateful to Dr. Amr Lotfy Farag, Lecturer of Radiation Oncology, Ain Shams University, for his guidance that enriched this work. And I am also indebted to Dr. Shahera Ahmed, Medical Doctor of Radiodiagnosis, Ain Shams University, who helped a great deal to complete this work.

My thanks also go to Mr. Abd Elgawad Khalefa, Psychologist, Psychiatry Center, Ain Shams University. For his active participation in completing this work.

Last, but by no means least, I am grateful to my wonderful family and to the patients and their parents to whom I dedicate my work.

Fatma Sayed Sayed Mahrous

Contents.

1.	Introduction1
2.	Hypothesis
3.	Aim of Work
4.	Review of Literature
Chapte	er1: Juvenile Rheumatoid Arthritis4
Chapte	er 2: Psychiatric Morbidity in Juvenile Rheumatoid Arthritis24
Chapte	er 3: Brain Single Photon Emission Computed Tomography45
5.Stud	ly Groups and Methods
6.Stati	stics
7. Res	ults58
8.Disc	eussion
9.Sum	mary87
10.Co	nclusion92
11.Re	commendations93
12.Re	ferences94
13. A	ppendix
14.Ar	rabic Summary

List of Abbreviations

ACA = Anti Centromere Antibody.

ACR = American College of Rheumatology.

ACTH = Adrenocorticotrophic Hormone.

ALL = Acute Lymphoblastic Leukaemia.

APF = Anti Perinuclear Factor.

AS = Ankylosing Spondylitis.

ASPs = American Affected Sib Pairs.

C2 = Type 2 Collagen.

CBC = Complete Blood Count.

CFS = Chronic Fatigue Syndrome.

CNS = Central Nervous System.

CRH = Corticosteroid Releasing Hormone.

CRP = C Reactive Protein.

CRT = Cathode Ray Tube.

CT = Computed Tomography.

ECS = Expected Correct Score.

EEG = Electroencephalogram.

ESR = Erythrocyte Sedimentation Rate.

ELAR = European League Against Rheumatism

EES = Expected Error Score

GHQ = General Health Questionnaire.

Gm- CSF = Granulocyte Colony Stimulating Factor.

GR = Growth Retardation.

HLA = Human Leucocytic Antigen.

HMPAO = Hexa Methyle Propylene Amine Oxime.

HPA axis = Hypothalamic Pituitary Adrenal axis.

HPG axes = Hypothalamic Pituitary Gonadal axes.

HSM = Hepatosplenomegaly.

IBD = Inflammatory Bowel Disease.

IQ = Intelligence Quotient.

IL = Interleukin.

ILAR = International League Against Rheumatism.

INF = Interferon.

IV = Intravenous.

JCA = Juvenile Chronic Arthritis.

JIA = Juvenile Idiopathic Arthritis.

JRA = Juvenile Rheumatoid Arthritis.

MAS = Macrophage Activation Syndrome.

mCi = milli Curi.

MIS = Macrophage Idiopathic Syndrome.

MIF = Migration Inhibitory Factor.

MRA = Magnetic Resonance Angiography.

MRI = Magnetic Resonance Imaging.

NSAIDs = Non Steroidal Anti Inflammatory Drugs.

OCS = Obtained Correct Score.

OES = Obtained Error Score.

PIQ = Performance Intelligence Quotient.

PET = Positron Emission Tomography.

PMTs = Photo Multiplier Tubes.

PHA = Pulse Height Analyzer.

QEEG = Quantified Electroencephalogram.

RA = Rheumatoid Arthritis.

RBPC = Revised Behavioral Problem Checklist.

r CBF = regional Cerebral Blood Flow.

RF = Rheumatoid Factor.

ROI = Region of Interest.

RR = Relative Risk.

SJIA = Systemic Juvenile Idiopathic Arthritis.

So JIA = Systemic onset Juvenile Idiopathic Arthritis.

SJRA = Systemic Juvenile Rheumatoid Arthritis.

So JRA = Systemic onset Juvenile Rheumatoid Arthritis.

SLE = Systemic Lupus Erythematosis.

SPECT = Single Photon Emission Computed Tomography.

SSR = Sleep Self Report.

TH1 = T Helper 1.

TIQ = Total Intelligence Quotient.

TMJ = Tempro Mandibular Joint.
TNF = Tumor Necrosis Factor.
VIQ = Verbal Intelligence Quotient.
WIS = Whechsler Intelligence Scale.
iii
111

List of Figures

Figure N°	Page Nº
Fig (1) A Proposed integrated bio psychosocial model of how	
stressors may impact on RA disease activity and related outcomes	29
Fig (2) Typical cerebral SPECT scan of a patient with attentional,	
executive and visuo- spatial disorders: there is hypo perfusion of the	44
frontal (more evident) and right parietal lobe.	
Fig (3) Cerebral SPECT scan of a patient with normal performances	
in all Psychometric tests: there is normal perfusion of the whole	44
brain.	
Fig (4) Gender distribution in the studied sample.	59
Fig (5) Family history of juvenile idiopathic arthritis in the patients.	59
Fig (6) Type of onset in juvenile idiopathic arthritis patients.	60
Fig (7) Disease activity status in the JIA patients.	61
Fig (8) Type of juvenile idiopathic arthritis and	64
gender in patients group.	

List of Tables

Table Nº	Page Nº
Table(1) The new classification of	
juvenile idiopathic arthritis,	9
clinical criteria and comparison to	
juvenile rheumatoid arthritis.	
Table(2) Differential diagnosis of	
juvenile arthritis.	20
Table(3) Age distribution in the	
studied sample.	58
Table(4) Gender distribution in	
the studied sample.	58
Table (5) Rheumatoid factor	
estimation among patients.	60
Table (6) Variation of disease	
activity with JIA onset type.	61
Table(7) Psychiatric morbidity in	
Patients group.	62
Table(8) Comparison between	
patients and controls	62
in behavioral functions.	
Table(9) Comparison between	
patients and controls in cognitive	63
functions.	
Table(10) Comparison between	
patients and controls	64
in General Health Questionnaire	
(GHQ).	
Table(11) Correlation between	
drug therapy(dose and duration)	
and behavioral and cognitive	65

Table(12) Comparison between the JIA patients and controls in brain perfusion by SPECT. 66 Table(13)Effect of disease activity on brain perfusion in the JIA 66 patients group. Table(14) Relation of rheumatoid factor to brain perfusion in 67 patients group. Table (15) Correlation between behavioral and cognitive 68 functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) 71 and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose and duration).	functions in patients group.	
in brain perfusion by SPECT. Table(13)Effect of disease activity on brain perfusion in the JIA patients group. Table(14) Relation of rheumatoid factor to brain perfusion in patients group. Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	Table(12) Comparison between	
Table(13)Effect of disease activity on brain perfusion in the JIA patients group. Table(14) Relation of rheumatoid factor to brain perfusion in patients group. Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	the JIA patients and controls	
on brain perfusion in the JIA patients group. Table(14) Relation of rheumatoid factor to brain perfusion in patients group. Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	in brain perfusion by SPECT.	66
patients group. Table(14) Relation of rheumatoid factor to brain perfusion in patients group. Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	Table(13)Effect of disease activity	
group. Table(14) Relation of rheumatoid factor to brain perfusion in patients group. Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	on brain perfusion in the JIA	66
Table(14) Relation of rheumatoid factor to brain perfusion in patients group. Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	patients	
factor to brain perfusion in patients group. Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	group.	
patients group. Table (15) Correlation between behavioral and cognitive 68 functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group 70 in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) 71 and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy 73 (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe 74 perfusion and drug therapy (dose	Table(14) Relation of rheumatoid	
Table (15) Correlation between behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	factor to brain perfusion in	67
behavioral and cognitive functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	patients group.	
functions and brain perfusion in the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	Table (15) Correlation between	
the JIA patients. Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	behavioral and cognitive	68
Table(16) Comparison between depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	functions and brain perfusion in	
depression group and control group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	the JIA patients.	
group in brain perfusion. Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	Table(16) Comparison between	
Table(17) Comparison between anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	depression group and control	70
anxiety group and control group in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	group in brain perfusion.	
in brain perfusion. Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	Table(17) Comparison between	
Table(18) Correlation between drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	anxiety group and control group	70
drug therapy (duration and dose) and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	in brain perfusion.	
and brain perfusion in patients group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	Table(18) Correlation between	
group. Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	drug therapy (duration and dose)	71
Table(19) Correlation between attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	and brain perfusion in patients	
attention problem, drug therapy (dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	group.	
(dose and duration) and frontal and parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe 74 perfusion and drug therapy (dose	Table(19) Correlation between	
parietal lobes perfusion. Table(20) Correlation between psychotic behavior, parietal lobe perfusion and drug therapy (dose	attention problem, drug therapy	73
Table(20) Correlation between psychotic behavior, parietal lobe 74 perfusion and drug therapy (dose	(dose and duration) and frontal and	
psychotic behavior, parietal lobe 74 perfusion and drug therapy (dose	parietal lobes perfusion.	
perfusion and drug therapy (dose	Table(20) Correlation between	
	psychotic behavior, parietal lobe	74
and duration).	perfusion and drug therapy (dose	
	and duration).	

Table(21) Effect of disease status	
on psychotic behavior and	74
attention problem.	
Table (22) Frontal lobe perfusion	
in relation to, depression and	75
disease status.	
Table (23) Parietal lobe perfusion	
in relation to sex, depression and	75
disease status	
Table (24) Frontal lobe perfusion	
in relation to drug therapy (dose	76
and duration)and psychotic	
behavior.	
Table (25) Parietal lobe perfusion	
in relation to drug therapy (dose	76
and duration)and psychotic	
behavior.	

Introduction

Juvenile Rheumatoid Arthritis (JRA) is one of the most common rheumatic diseases of children and a major cause of chronic physical disability. It is characterized by an idiopathic synovitis of the joints associated with soft tissue swelling and effusion (Miller and Cassidy, 2004). The American College of Rheumatology criteria classify it as a category of diseases with three principle types of onset (1)Oligoarthritis (2)Polyarthritis – and (3) Systemic onset disease (Miller and Cassidy, 2000).

Juvenile Idiopathic Arthritis (JIA) arises before 16 years of age and lasts for more than 6 months. A serious problem in juvenile idiopathic arthritis is skeletal growth retardation, osteopenia and greater risk of developing fractures (Quarta et al., 2005). The damage to the cartilaginous tissue is often irreversible and responsible for much of the morbidity (Mine et al., 2006).

Systemic onset disease is characterized by presence of fever, faint erythematous macular rash, visceral involvement including hepatosplenomegaly ,lymphadenopathy and serositis such as pericardial effusion (Miller and Cassidy , 2000).

Although systemic onset (JRA) accounts for only about 20% of most reported series, children with systemic onset (JRA) are often the most difficult to treat. Many children have marked physical and emotional disability as a result of both disease and treatment – related morbidities (Adams and Lehaman, 2005).

Juvenile rheumatic diseases have important impacts on health, on patient's body functions and structures, activities, and social participation (Minden., 2006). Juvenile rheumatoid arthritis is a chronic painful disorder with adverse psychological sequalae that might influence the outcome of the disease and its treatment (Mullick et al., 2005). Children with chronic illness have increased rates of mental health problems and psychological difficulties (Glazebrook et al., 2003). Psychological factors may play a more active role in debilitating pediatric patients with JRA (Carter et al., 1999).

The long duration of illness is associated with higher proportion of cases with psychiatric disorders, the diagnoses in decreasing order were depression disorder 15%, somatoform disorder 12.5%, adjustment disorder 5% and mixed anxiety and depression disorder 2.5% (Mullick et al., 2005). The strongest predictors of depression were high tension and low self esteem, fatigue, passive coping, pain, and physical disability (Covic et al., 2006). Sleep abnormalities are common in children

with JRA including night awaking, parasomnias, sleep anxiety, sleep disordered breathing and morning waking / daytime sleepiness (**Bloom et al., 2002**).

Bartolini et al (2002) detected in 38% of patients with JRA some difficulties in mental flexibility. These poor performances are related to hypo perfusion of the frontal and parietal lobes as detected by brain Single Photon Emission Computed Tomography (SPECT), while **Pedersen et al (1998)** stated that in an adolescent with JRA, there was vasculitis of the anterior and middle cerebral arteries evident in Magnetic Resonance Angiography (MRA).

Hypothesis

This study hypothesizes that there is psychiatric morbidity in JRA This psychiatric morbidity is accompanied with SPECT changes.

Aim of the study

This study is aimed at:

- 1) Detection of psychiatric morbidity in children and adolescents with JRA
- 2) Correlation between psychiatric morbidity and duration of illness.
- 3)Detection of cognitive dysfunction in children and adolescents with JRA..
- 4) Correlation of psychiatric morbidity to SPECT findings.

Chapter 1

Juvenile Rheumatoid Arthritis

Juvenile rheumatoid arthritis (JRA) is one of the most common rheumatic diseases of children and a major cause of chronic physical disability. It is characterized by an idiopathic synovitis of the peripheral joints, associated with soft tissue swelling and effusion (Miller and Cassidy, 2004). It is also called juvenile chronic arthritis (JCA) or juvenile idiopathic arthritis (JIA) (Patel and Goldstein, 2003).

Epidemiology:-

Incidence and Prevalence:-

Early epidemiologic studies showed that the prevalence ranged from 0.16 to 1.10\1000 and the incidence ranged from 0 to 9.2 \100,1000 (Schneider and Passo, 2002). Epidemiological incidence in Egypt in1994 provided an incidence of 9.3 cases per 100,1000 per year (yr) (El -Gamal, 1996). In another study, El-Gamal et al., 1999 reported that the incidence of JRA in relation to outpatient clinic in Children's Hospital of Ain Shams University during the year 1994 was 9.8\100.000.

Oligoarthritis represents the most common onset type of juvenile idiopathic arthritis (JIA) in both Europe and North America accounting for 50 to 75 % of all cases with a meta – analysis producing an overall 58 % estimate within population based studies (Borchers et al., 2006).

Interestingly, in Northern Europe,66% of cases were oligoarticular onset type of JIA when the European League Against Rheumatism (EULAR) criteria were used. This figure decreasedto46% when International League Against Rheumatism (ILAR) criteria were used (Berntson et al., 2003). Of note between 20 and 30 % of patients with oligoarticular onset of JIAdevelop a polyarticular disease course (Fantini et al., 2003).

Age of Onset and Sex Distribution:-

The average age of onset is 6 yrs with peaks between 1 and 6 yrs, and another peak between 9 and 14 yrs .Girls are affected more frequently than boys (**Glueck and Gollman, 2005**).